---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-055007"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2024-04-30T23:59:59+00:00"
generated_at: "2026-06-03T04:40:45.665859+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TriSalus Life Sciences secures up to $50M debt financing from OrbiMed; $25M funded at close

## Summary
- $25M funded on April 30, 2024; up to $25M additional available in two tranches subject to revenue thresholds.
- Loan matures April 2029; interest rate is SOFR plus 8.50% (floor 4% SOFR); initial 15 months may accrue up to 3.5% PIK interest.
- Issued OrbiMed warrant to purchase 130,805 shares at $9.5562; also registration rights agreement filed.
- Company expects cash runway through 2025, targeting break-even EBITDA for TriNav business in 2025.
- Covenants require minimum unrestricted cash of $5M (before March 31, 2025) and $10M thereafter.

## SEC filing metadata
- accession: 0001104659-24-055007
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2024-04-30T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000110465924055007/0001104659-24-055007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000110465924055007/tm2413063d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-055007
- JSON: https://secwatch.observer/filing/0001104659-24-055007.json
- Plain text: https://secwatch.observer/filing/0001104659-24-055007.txt

## Key facts
- Debt Financings
  TriSalus Life Sciences, Inc. incurred credit facility of $25 million with OrbiMed Royalty & Credit Opportunities IV, LP at SOFR plus 8.50% maturing April 30, 2029.
  - Instrument: credit facility
  - Principal: $25 million
  - Counterparty: OrbiMed Royalty & Credit Opportunities IV, LP
  - Rate: SOFR plus 8.50%
  - Maturity: April 30, 2029
  - Event: incurrence
  source text: On April 30, 2024, the Borrower borrowed the Initial Commitment Amount, resulting in gross proceeds to the Borrower of $25 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000110465924055007/0001104659-24-055007-index.htm
- Material Agreements
  TriSalus Life Sciences, Inc. entered into Credit Agreement with OrbiMed Royalty & Credit Opportunities IV, LP valued at Up to $50 million senior secured credit facility, $25 million initial borrowing on April 30, 2024, $ (effective 2024-04-30).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: OrbiMed Royalty & Credit Opportunities IV, LP
  - Value: Up to $50 million senior secured credit facility, $25 million initial borrowing on April 30, 2024, $
  - Effective: 2024-04-30
  source text: On April 30, 2024 (the “ Closing Date ”), TriSalus Life Sciences, Inc., a Delaware corporation (the “ Company ”) and TriSalus Operating Life Sciences, Inc., a Delaware corporation and wholly owned subsidiary of the Company (the “ Borrower ”) entered into a Credit Agreement (the “ Credit Agreement ”), by and between the Company, as parent, the Borrower, as borrower, OrbiMed Royalty & Credit Opportunities IV, LP, a Delaware limited partnership (the “ Initial Lender ”), as a lender, and each other lender that may from time to time become a party thereto (each, including the Initial Lender, and together with their affiliates, successors, transferees and assignees, the “ Lenders ”), and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent for the Lenders (in such capacity, the “ Administrative Agent ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000110465924055007/0001104659-24-055007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.